C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations

Authors

  • Roshaan Fatima Department of Internal Medicine, Benazir Bhutto Hospital, Rawalpindi, Pakistan
  • Rizwan Mahmud Department of Internal Medicine, Benazir Bhutto Hospital, Rawalpindi, Pakistan
  • Shahzad Manzoor Department of Internal Medicine, Benazir Bhutto Hospital, Rawalpindi, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v6i12.2195

Keywords:

Chronic obstructive pulmonary disease, C-reactive protein, acute exacerbation, antibiotic prescribing, antimicrobial stewardship, point-of-care testing.

Abstract

Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are commonly treated with antibiotics, although bacterial infection is not present in all cases. Overprescription contributes to antimicrobial resistance and unnecessary healthcare costs. Biomarkers such as C-reactive protein (CRP) may help clinicians guide more appropriate antibiotic use. Objective: To determine whether C-reactive protein (CRP)–guided antibiotic prescribing reduces antibiotic use in patients with acute exacerbations of chronic obstructive pulmonary disease. Methods: A randomized controlled trial was conducted at Benazir Bhutto Hospital in Rawalpindi from 11 June 2025 to 11 November 2025. A total of 174 patients aged ≥40 years with confirmed COPD presenting with AECOPD were enrolled and randomly allocated into two groups (87 patients each). The intervention group received CRP-guided care in which point-of-care CRP testing was performed, and antibiotics were prescribed only when CRP levels exceeded 20 mg/L. The control group received standard care based on clinical assessment and physician judgment without CRP testing. Patients were followed for four weeks to evaluate antibiotic prescription rates. Data were analyzed using SPSS version 25.0. Categorical variables were compared using the Chi-square test and continuous variables using the Student’s t-test. A p-value <0.05 was considered statistically significant. Results: Baseline demographic and clinical characteristics were comparable between the two groups. At the initial consultation, antibiotics were prescribed to 36.7% of patients in the CRP-guided group compared with 77% in the standard care group (χ²=28, p<0.0001). At four-week follow-up, antibiotic prescription rates were 10.3% in the CRP-guided group and 89.6% in the standard care group (χ²=109, p<0.0001), demonstrating a marked reduction in antibiotic utilization in the intervention group. Conclusion: CRP-guided antibiotic prescribing significantly reduces antibiotic utilization among patients with acute exacerbations of COPD compared with standard clinical judgment alone. Incorporating CRP testing into routine clinical practice may help promote rational antibiotic use in the management of AECOPD.

Downloads

Download data is not yet available.

References

Hicks LA, Bartoces MG, Roberts RM, Suda KJ, Hunkler RJ, Taylor TH Jr, et al. US outpatient antibiotic prescribing variation according to geography, patient population, and provider specialty in 2011. Clin Infect Dis. 2015;60(9):1308-16. https://doi.org/10.1093/cid/civ076

Schroeck JL, Ruh CA, Sellick JA Jr, Ott MC, Mattappallil A, Mergenhagen KA. Factors associated with antibiotic misuse in outpatient treatment for upper respiratory tract infections. Antimicrob Agents Chemother. 2015;59(7):3848-52. https://doi.org/10.1128/AAC.00652-15

O’Neill J. Rapid diagnostics: stopping unnecessary use of antibiotics. London: Review on Antimicrobial Resistance; 2015.

Verbakel JY, Turner PJ, Thompson MJ, Plüddemann A, Price CP, Shinkins B, et al. Common evidence gaps in evaluating point-of-care diagnostic tests: a review of Horizon Scan reports. BMJ Open. 2017;7(9):e015760. https://doi.org/10.1136/bmjopen-2016-015760

Kunadharaju R, Sethi S. Treatment of acute exacerbations in chronic obstructive pulmonary disease. Clin Chest Med. 2020;41(3):439-51. https://doi.org/10.1016/j.ccm.2020.06.008

Bollmeier SG, Hartmann AP. Management of chronic obstructive pulmonary disease: a review focusing on exacerbations. Am J Health Syst Pharm. 2020;77(4):259-68. https://doi.org/10.1093/ajhp/zxz306

Tickoo M, Ruthazer R, Bardia A, Doron S, Andujar-Vazquez GM, Gardiner BJ, et al. The effect of respiratory viral assay panel on antibiotic prescription patterns at discharge in adults admitted with mild to moderate acute exacerbation of COPD: a retrospective before-and-after study. BMC Pulm Med. 2019;19(1):118. https://doi.org/10.1186/s12890-019-0872-0

Gillespie D, Butler C, Bates J, Hood K, Melbye H, Phillips R, et al. Associations with antibiotic prescribing for acute exacerbation of COPD in primary care: secondary analysis of a randomised controlled trial. Br J Gen Pract. 2021;71(705):e266-e272. https://doi.org/10.3399/BJGP.2020.0823

Hurst JR, Donaldson GC, Perera WR, Wilkinson TMA, Bilello JA, Hagan GW, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006;174(8):867-74. https://doi.org/10.1164/rccm.200604-506OC

Minnaard MC, van de Pol AC, de Groot JAH, de Wit NJ, Hopstaken RM, van Delft S, et al. The added diagnostic value of five different C-reactive protein point-of-care test devices in detecting pneumonia in primary care: a nested case-control study. Scand J Clin Lab Invest. 2015;75(4):291-5. https://doi.org/10.3109/00365513.2015.1006136

Llor C, Moragas A, Hernández S, Bayona C, Miravitlles M. Efficacy of antibiotic therapy for acute exacerbations of mild to moderate chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012;186(8):716-23. https://doi.org/10.1164/rccm.201206-0996OC

Butler CC, Gillespie D, White P, Bates J, Lowe R, Thomas-Jones E, et al. C-reactive protein testing to guide antibiotic prescribing for COPD exacerbations. N Engl J Med. 2019;381(2):111-20. https://doi.org/10.1056/NEJMoa1803185

Prins HJ, Duijkers R, van der Valk P, Schoorl M, Daniels JMA, van der Werf TS, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019;53(5):1802014. https://doi.org/10.1183/13993003.02014-2018

Hoult G, Gillespie D, Wilkinson TMA, Thomas M, Francis NA. Biomarkers to guide the use of antibiotics for acute exacerbations of COPD (AECOPD): a systematic review and meta-analysis. BMC Pulm Med. 2022;22(1):194. https://doi.org/10.1186/s12890-022-01958-4

Llor C. C-reactive protein point-of-care testing to guide antibiotic prescribing for respiratory tract infections. Expert Rev Respir Med. 2025;19(8):863-77. https://doi.org/10.1080/17476348.2025.2510378

Alam M, Saleem Z, Haseeb A, Qamar MU, Sheikh A, Abuhussain SSA, et al. Tackling antimicrobial resistance in primary care facilities across Pakistan: current challenges and implications for the future. J Infect Public Health. 2023;16 Suppl 1:97-110. https://doi.org/10.1016/j.jiph.2023.10.046

Phillips R, Stanton H, Singh-Mehta A, Gillespie D, Bates J, Gal M, et al. C-reactive protein-guided antibiotic prescribing for COPD exacerbations: a qualitative evaluation. Br J Gen Pract. 2020;70(696):e505-e513. https://doi.org/10.3399/bjgp20X709865

Downloads

Published

2025-12-31

How to Cite

Fatima, R. ., Mahmud, R. ., & Manzoor, S. . (2025). C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations. Biological and Clinical Sciences Research Journal, 6(12), 39–41. https://doi.org/10.54112/bcsrj.v6i12.2195

Issue

Section

Original Research Articles